Compositions and methods for treating the eye

Patent metadata

Field	Value
Publication number	US-2020030394-A1
Application number	US-201916519149-A
Country	US
Kind code	A1
Filing date	Jul 23, 2019
Priority date	Jul 27, 2018
Publication date	Jan 30, 2020
Grant date	—

Abstract

The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of hyaluronic acid from and/or in the cornea, and methods of using the compositions to treat the eye.

First claim

What is claimed is:

1 . A method for treating a patient having decreased or low-level production/release/delivery/excretion of hyaluronic acid from and/or in the cornea comprising the step of topically administering to the eye of the patient a composition comprising:
iv) a safe and effective amount of one or more extracts, or sources of extracts, of the genus Pichia to achieve a Pichia genus extract concentration in the corneal fluid in the corneal tissues of the eye of at least about 0.3 mg/ml; v) optionally, a safe and effective amount of a permeation enhancer; and vi) optionally, an ophthalmologically acceptable carrier.

2 . The method of claim 1 wherein the Pichia genus extract in the composition comprises oligosaccharides and polysaccharide having a weight average molecular weight of from about 180 to about 800,000 Da.

3 . The method of claim 1 wherein the Pichia genus extract in the composition comprises oligosaccharides and polysaccharide having an average degree of polymerization of from DP 1 to DP 4444.

4 . The method of claim 1 , wherein the composition comprises a permeation enhancer.

5 . The method according to claims 1 and/or 2 wherein the permeation enhancer is present at a concentration of from about 0.01% to about 20% (w/v) of the total composition.

6 . The method of claim 3 wherein the permeation enhancer is present at a concentration of from about 0.1% to 10% (w/v) of the total composition.

7 . The method of claim 4 wherein the permeation enhancer is present at a concentration of from about 0.25% to 5% (w/v) of the total composition,

8 . The method of claim 4 wherein the permeation enhancer is selected from polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid and derivatives thereof, EDTA, disodium EDTA, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, urosdeoxycholic acid, saponins, glycyrrhizic acid, ammonium glycyrrhizide, decamethonium, decamethonium bromide, and dodecyltrimethylammonium bromide or mixtures of any of the above.

9 . The method of claim 1 , wherein the composition is administered when the hyaluronic acid concentration, in the patient's tears, is lower than about 10 nanograms per milligram of proteins.

10 . The method of claim 1 , wherein the composition is administered when the hyaluronic acid concentration, in the patient's tears, is lower than about 15 nanograms per milligram of proteins.

11 . The method of claim 1 , wherein the composition is administered when the hyaluronic acid concentration, in the patient's tears, is lower than about 20 nanograms per milligram of proteins.

12 . The method of claim 1 , wherein the composition is administered when the hyaluronic acid concentration, in the patient's tears, is lower than about 25 nanograms per milligram of proteins.

13 . The method of claim 1 , wherein the composition is administered to the patient's eye to raise the concentration of hyaluronic acid in the patient's tears to be equal to or greater than about 10 nanograms per milligram of proteins.

14 . The method of claim 1 , wherein the composition is administered to the patient's eye to raise the concentration of hyaluronic acid in the patient's tears to be equal to or greater than about 15 nanograms per milligram of proteins.

15 . The method of claim 1 , wherein the composition is administered to the patient's eye to raise the concentration of hyaluronic acid in the patient's tears to be equal to or greater than about 20 nanograms per milligram of proteins.

16 . The method of claim 1 , wherein the composition is administered to the patient's eye to raise the concentration of hyaluronic acid in the patient's tears to be equal to or greater than about 25 nanograms per milligram of proteins.

Assignees

• Johnson & Johnson Vision Care

Inventors

• Li Wen-Hwa Ting
• Mahmood Khalid
• Parsa Ramine
• Randhawa Manpreet
• Bai Mingqi
• Holeva Kenneth T

Classifications

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title

• A61K36/064 Primary

  Saccharomycetales, e.g. baker's yeast · CPC title

• A61K9/0048 Primary

  Eye, e.g. artificial tears · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/38

  Cellulose; Derivatives thereof · CPC title